Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.55 |
| ▸ | TTK | P33981 | 9/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269579 | 0.81 | FLT3 (0.55) | FLT3TTKBACE1BACE2AURKA | |
| SCHEMBL9937301 | 0.80 | TTK (0.57) | FLT3TTKTLR7ADORA3 | |
| SCHEMBL5399557 | 0.78 | TTK (0.61) | FLT3TTK | |
| SCHEMBL5398375 | 0.77 | FLT3 (0.41) | FLT3TTKADORA3 | |
| SCHEMBL5413848 | 0.76 | TTK (0.65) | FLT3TTK | |
| SCHEMBL12288576 | 0.76 | BACE1 (0.44) | FLT3TTKBACE1BACE2AURKA | |
| SCHEMBL8239708 | 0.75 | AURKA (0.62) | FLT3TTKAURKAAURKB | |
| SCHEMBL5404510 | 0.75 | FLT3 (0.48) | FLT3TTKBACE1BACE2ADORA3 | |
| SCHEMBL12272071 | 0.74 | FLT3 (0.86) | FLT3TTK | |
| SCHEMBL5398296 | 0.73 | ADORA3 (0.53) | FLT3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2686319-A1 | IMIDAZO PYRAZINES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2010069684-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-06-24 | — | — | WO | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885TTK 69/4885BACE1 2815/4885 |
| US-20120238564-A1 | IMIDAZO PYRAZINES | THPO, MCL1, IKZF3 | FLT3 5/4885TTK 2825/4885BACE1 4756/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | FLT3 215/4885TTK 369/4885BACE1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.